Akebia Competitors
| AKBA Stock | USD 1.38 0.03 2.13% |
Akebia Ther vs Zevra Therapeutics Correlation
Poor diversification
The correlation between Akebia Ther and ZVRA is 0.68 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Akebia Ther and ZVRA in the same portfolio, assuming nothing else is changed.
Moving together with Akebia Stock
Moving against Akebia Stock
| 0.78 | DSGN | Design Therapeutics | PairCorr |
| 0.6 | ENGN | enGene Holdings Common | PairCorr |
| 0.52 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.44 | KYTX | Kyverna Therapeutics | PairCorr |
| 0.43 | 63E | ONWARD MEDICAL BV | PairCorr |
Akebia Ther Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Akebia Ther and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Akebia and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Akebia Ther does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Akebia Stock performing well and Akebia Ther Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Akebia Ther's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| CRVS | 6.43 | 3.01 | 0.66 | (0.32) | 2.83 | 9.63 | 174.29 | |||
| PRTA | 2.28 | (0.32) | 0.00 | (0.18) | 0.00 | 4.76 | 13.99 | |||
| OLMA | 6.24 | 2.43 | 0.64 | 1.58 | 2.96 | 9.82 | 145.73 | |||
| GOSS | 3.93 | 0.22 | 0.05 | 0.21 | 4.65 | 8.77 | 27.11 | |||
| RIGL | 3.93 | 0.41 | 0.10 | 0.33 | 3.87 | 8.66 | 44.65 | |||
| KALV | 3.15 | 0.61 | 0.16 | 0.51 | 3.09 | 8.43 | 25.15 | |||
| VTYX | 4.05 | 1.19 | 0.25 | (20.31) | 3.38 | 12.92 | 37.04 | |||
| CMPX | 2.96 | 0.84 | 0.24 | 1.23 | 2.65 | 7.61 | 16.90 | |||
| FDMT | 3.82 | (0.19) | 0.00 | (0.17) | 0.00 | 6.52 | 27.09 | |||
| ZVRA | 2.19 | (0.20) | 0.00 | 0.66 | 0.00 | 4.00 | 13.65 |
Cross Equities Net Income Analysis
Compare Akebia Ther and related stocks such as Corvus Pharmaceuticals, Prothena plc, and Olema Pharmaceuticals Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRVS | (176 K) | (176 K) | (176 K) | (176 K) | (176 K) | (31.3 M) | (36.4 M) | (55.7 M) | (46.9 M) | (43.7 M) | (4.8 M) | (43.2 M) | (41.3 M) | (27 M) | (62.3 M) | (56.1 M) | (58.9 M) |
| PRTA | (12.5 M) | (29.7 M) | (41.4 M) | (41 M) | (7.2 M) | (80.6 M) | (160.1 M) | (153.2 M) | (155.6 M) | (77.7 M) | (111.1 M) | 67 M | (116.9 M) | (147 M) | (122.3 M) | (110.1 M) | (115.6 M) |
| OLMA | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (4.3 M) | (22.1 M) | (71.1 M) | (102.6 M) | (96.7 M) | (129.5 M) | (116.5 M) | (110.7 M) |
| GOSS | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (6.8 M) | (147 M) | (180.8 M) | (243.4 M) | (234 M) | (229.4 M) | (179.8 M) | (56.5 M) | (50.9 M) | (53.4 M) |
| RIGL | (12.4 M) | (86 M) | (98.8 M) | (89 M) | (90.9 M) | (51.5 M) | (69.2 M) | (78 M) | (70.5 M) | (66.5 M) | (29.7 M) | (17.9 M) | (58.6 M) | (25.1 M) | 17.5 M | 15.7 M | 16.5 M |
| KALV | (2.1 M) | (2.1 M) | (2.1 M) | (5.7 M) | (13.4 M) | (24.8 M) | (18.6 M) | (15.8 M) | (20.8 M) | (29.1 M) | (46.2 M) | (82.3 M) | (92.9 M) | (126.6 M) | (183.4 M) | (24.8 M) | (26.1 M) |
| VTYX | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (28.2 M) | (83.7 M) | (108.4 M) | (193 M) | (135.1 M) | (121.6 M) | (127.7 M) |
| CMPX | (38.3 M) | (38.3 M) | (38.3 M) | (38.3 M) | (38.3 M) | (38.3 M) | (38.3 M) | (38.3 M) | (38.3 M) | (34.7 M) | (29.5 M) | (82.2 M) | (39.2 M) | (42.5 M) | (49.4 M) | (44.4 M) | (46.7 M) |
| FDMT | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (9.6 M) | (49.3 M) | (56.7 M) | (68.3 M) | (101.1 M) | (100.8 M) | (160.9 M) | (144.8 M) | (137.5 M) |
| ZVRA | (70.4 K) | (70.4 K) | (70.4 K) | (5.2 M) | (24.5 M) | (54.7 M) | (16.5 M) | (43.4 M) | (56.5 M) | (24.5 M) | (12.8 M) | (8.6 M) | (26.8 M) | (46 M) | (105.5 M) | (95 M) | (90.2 M) |
Akebia Ther and related stocks such as Corvus Pharmaceuticals, Prothena plc, and Olema Pharmaceuticals Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Akebia Ther financial statement analysis. It represents the amount of money remaining after all of Akebia Ther operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Akebia Ther Competitive Analysis
The better you understand Akebia Ther competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Akebia Ther's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Akebia Ther's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Akebia Ther Competition Performance Charts
Five steps to successful analysis of Akebia Ther Competition
Akebia Ther's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Akebia Ther in relation to its competition. Akebia Ther's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Akebia Ther in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Akebia Ther's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Akebia Ther, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Akebia Ther position
In addition to having Akebia Ther in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Strategy ETFs Thematic Idea Now
Strategy ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Strategy ETFs theme has 1748 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Strategy ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Akebia Ther Correlation with its peers. For information on how to trade Akebia Stock refer to our How to Trade Akebia Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akebia Ther. If investors know Akebia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Akebia Ther assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.08) | Revenue Per Share | Quarterly Revenue Growth 0.57 | Return On Assets | Return On Equity |
Akebia Ther's market price often diverges from its book value, the accounting figure shown on Akebia's balance sheet. Smart investors calculate Akebia Ther's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Akebia Ther's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Akebia Ther's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Akebia Ther represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Akebia Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.